These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3244103)

  • 1. Human serum and plasma protein binding of enoximone and its sulfoxide metabolite.
    Hook RH; Boxenbaum H; Thompson GA; Okerholm RA
    J Pharm Sci; 1988 Dec; 77(12):1012-7. PubMed ID: 3244103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral enoximone pharmacokinetics in patients with congestive heart failure.
    Lima JJ; Leier CV; Holtz L; Sterechele J; Shields BJ; MacKichan JJ
    J Clin Pharmacol; 1987 Sep; 27(9):654-60. PubMed ID: 2960700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automatic preparation of human serum samples for analysis of the drug enoximone and its sulphoxide metabolite using high-performance liquid chromatography.
    Cooper JD; Turnell DC
    J Chromatogr; 1986 Jul; 380(1):109-16. PubMed ID: 2943750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite.
    Okerholm RA; Chan KY; Lang JF; Thompson GA; Ruberg SJ
    Am J Cardiol; 1987 Aug; 60(5):21C-26C. PubMed ID: 2956863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous analysis of a new cardiotonic agent, MDL 17,043, and its major sulfoxide metabolite in plasma by high-performance liquid chromatography.
    Chan KY; Ohlweiler DF; Lang JF; Okerholm RA
    J Chromatogr; 1984 Mar; 306():249-56. PubMed ID: 6232282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous enoximone in dialysis patients.
    Fiegel P; Trenk D; Jaehnchen E; Dieterich HA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S20-3. PubMed ID: 2480480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the serum protein binding of oxycodone and morphine using ultrafiltration.
    Leow KP; Wright AW; Cramond T; Smith MT
    Ther Drug Monit; 1993 Oct; 15(5):440-7. PubMed ID: 8249052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of enoximone and its principle metabolite in serum and urine using high pressure liquid chromatography].
    Tarral E; Jehl F; Gallion C; Monteil H
    Therapie; 1990; 45(1):1-6. PubMed ID: 2140472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration.
    David BM; Tjokrosetio R; Ilett KF
    Ther Drug Monit; 1983; 5(1):81-6. PubMed ID: 6845403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology and pharmacokinetics of enoximone].
    Jähnchen E; Trenk D
    Z Kardiol; 1991; 80 Suppl 4():21-6. PubMed ID: 1833893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic effects of enoximone in patients with congestive heart failure.
    Hohnloser SH; Zehender M; Geibel A; Meinertz T; Just H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S29-32. PubMed ID: 2480482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of fenoximone, a new cardiotonic, in healthy subjects.
    Alken RG; Belz GG; Haegele KD; Meinicke T; Schechter PJ
    Clin Pharmacol Ther; 1984 Aug; 36(2):209-16. PubMed ID: 6235081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR identification of endogenous metabolites interacting with fatted and non-fatted human serum albumin in blood plasma: Fatty acids influence the HSA-metabolite interaction.
    Jupin M; Michiels PJ; Girard FC; Spraul M; Wijmenga SS
    J Magn Reson; 2013 Mar; 228():81-94. PubMed ID: 23357430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of hepatic peroxisomal fatty acid beta-oxidation by enoximone.
    Abdel-Aleem S; Youssef J; Frangakis C; Badr M
    Life Sci; 1992; 51(1):53-7. PubMed ID: 1535408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of oral administration of enoximone on cardiac performance, arterial circulation at rest and on the vasoconstrictor effect of local noradrenaline infusions into the human hand vein].
    Breithaupt K; Belz GG; Kempinski S; Schicketanz KH; Dieterich HA
    Z Kardiol; 1991; 80 Suppl 4():15-20. PubMed ID: 1833892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum.
    Morin D; Simon N; Deprés-Brummer P; Lévi F; Tillement JP; Urien S
    Pharmacology; 1997 May; 54(5):271-5. PubMed ID: 9380773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and pharmacokinetics of enoximone.
    Dage RC; Okerholm RA
    Cardiology; 1990; 77 Suppl 3():2-13; discussion 27-33. PubMed ID: 2148277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of various degrees of cardiac failure, chronic medical treatment, and acute additional enoximone application on the parameters of the vasopressor system.
    Mitrovic V; Neuzner J; Husseini H; Volz M; Schlepper M
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S40-9. PubMed ID: 2480485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of theophylline in human serum determined by ultrafiltration and equilibrium dialysis.
    Brørs O; Sager G; Sandnes D; Jacobsen S
    Br J Clin Pharmacol; 1983 Apr; 15(4):393-7. PubMed ID: 6849773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting in vitro protein binding of etoposide in humans.
    Fleming RA; Evans WE; Arbuck SG; Stewart CF
    J Pharm Sci; 1992 Mar; 81(3):259-64. PubMed ID: 1640365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.